Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 26, 2025Expert Review of Cardiovascular TherapyOpen Access

Direct oral anticoagulants versus vitamin K antagonists in concurrent hypertrophic cardiomyopathy and atrial fibrillation: a meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMax AboutorabiMAMahmood AhmadKFKiran Flora

Discussion

Loading...

Member takes

Overview

Meta-analysis finds direct oral anticoagulants reduce thromboembolic events and bleeding in hypertrophic cardiomyopathy patients with atrial fibrillation, suggesting improved safety over vitamin K antagonists.

Key Points

  • Direct oral anticoagulants are associated with lower thromboembolic events than vitamin K antagonists in concurrent hypertrophic cardiomyopathy and atrial fibrillation.
  • In the analysis of 14,243 patients, DOACs showed significantly fewer major bleeds compared to VKAs, with an odds ratio of 0.54.
  • Apixaban and dabigatran demonstrated improved outcomes for thromboembolic events, major bleeding, and all-cause death compared to VKAs.
  • This analysis supports the use of DOACs as a safer alternative to VKAs in patients with hypertrophic cardiomyopathy and atrial fibrillation.

Cite This Study

Aboutorabi et al. (2025) studied this question.

synapsesocial.com/papers/689a0933e6551bb0af8ce4dbhttps://doi.org/10.1080/14779072.2025.2538563
View Full Paper
Ask AI
Bookmark
Share